John Sedivy
Co-founder
TT
Transposon Therapeutics, Inc.
Transposon Therapeutics develops nucleoside reverse transcriptase inhibitors (NRTIs) targeting LINE-1 reverse transcription to mitigate neurodegeneration associated with diseases such as Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis. Their lead candidate, TPN-101, aims to reduce neurotoxic pathology linked to increased LINE-1 activity, addressing a critical need for effective treatments in neurodegenerative disorders.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Neurodegenerative diseases like Progressive Supranuclear Palsy (PSP) and Amyotrophic Lateral Sclerosis (ALS) are associated with increased expression and reverse transcription of LINE-1 elements, leading to neurotoxic pathology and neuronal dysfunction. Current treatments do not effectively target the underlying LINE-1 activity contributing to these conditions. Aicardi-Goutières Syndrome (AGS) is caused by genetic mutations of LINE-1 repressing enzymes, resulting in uncontrolled LINE-1 activation with severe interferon-1 autoimmune reaction.
Solution
Transposon Therapeutics is developing nucleoside reverse transcriptase inhibitors (NRTIs) and Protein Kinase R inhibitors (PKRi) to address LINE-1 associated neurodegenerative diseases. Their lead candidate, TPN-101 (censavudine), is a potent inhibitor of LINE-1 reverse transcriptase with systemic and brain bioavailability, currently in Phase 2a clinical trials for PSP, ALS/FTD, and AGS. By inhibiting LINE-1 reverse transcription, TPN-101 aims to mitigate neurodegeneration and reduce neurotoxic pathology. Transposon is also developing next-generation NRTIs and PKR inhibitors to expand their pipeline and target additional neurological and age-related diseases associated with LINE-1 pathology.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as Progressive Supranuclear Palsy (PSP), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Aicardi-Goutières Syndrome (AGS), as well as those with other LINE-1 associated neurological and age-related diseases.
Features
- TPN-101: A nucleoside reverse transcriptase inhibitor (NRTI) targeting LINE-1 reverse transcriptase.
- Oral administration: TPN-101 is designed for once-daily oral dosing.
- Clinical trials: TPN-101 is currently under study in Phase 2a clinical trials for Progressive Supranuclear Palsy (PSP), Amyotrophic Lateral Sclerosis (ALS) / Frontotemporal Dementia (FTD), and Aicardi-Goutières Syndrome (AGS).
- Biomarker analysis: Clinical trials incorporate biomarker measurements to assess changes in inflammation and neurodegeneration.
- Next-generation NRTIs: Development of proprietary NRTIs for rapid exploration of new indications with LINE-1 related pathology.
- PKR inhibitors: Discovery program evaluating small molecule Protein Kinase R (PKR) inhibitors for treating compromised cognition and memory associated with central nervous system diseases.